Multicenter prospective escalation-deescalation PET-guided clinical study in classical type Hodgkin disease in the North-West of Russian Federation (RNWOHG-HD1): rationale and design

Afanasyev, Boris; Moiseev, Ivan S.; Алексеев, С. М.; Mikhailova, N.; Kondakova, Elena; Ilyin, N. V.; Belyaеv, Alexey M.; Zaritskey, Andrey; Медведева, Н. В.; Manikhas, Georgii; Voloshin, S.; Моисеенко, В.; Шнейдер, Т В; Transfusiology, St. Petersburg

doi:10.18620/ctt-1866-8836-2017-6-4-76-81

Cited by 4 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results obtained with anti-PD therapy of Hodgkin's disease should be compared with efficiency of Brentuximab, an immunotoxic drug targeted for CD30 antigen on tumor cells [27]. It proved to be highly efficient in resistant/relapsed cases of HD being currently under extensive trials [28][29][30]. Its combined effects with anti-PD drugs deserve further studies.…”

Section: Discussionmentioning

confidence: 99%

Safety and efficacy of nivolumab applied at different dosage in the patients with relapsing Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation

Lepik¹,

Andrey²,

Evgeniya³

et al. 2018

CTT

Self Cite

View full text Add to dashboard Cite

Allogeneic hematopoietic cell transplantation (allo-HSCT) is a potentially curative treatment for patients with relapsed and refractory Hodgkin lymphoma (HL) followed by long-term survival. However, relapse and progression of disease in the post-transplant period may occur in a substantial number of patients. nivolumab, an antibody blocking the programmed cell death receptor 1 (PD-1) has shown high efficiency in patients with HL in pre-and post-allo-HSCT setting. We have retrospectively assessed efficacy and toxicity of nivolumab as a single agent in seven HL patients relapsing after allo-HSCT using the drug at different doses (0.5 to 3 mg/kg body mass) administered every 2 weeks. We did not observe any cases of graft-versus-host disease (GVHD) after nivolumab initiation. An objective clinical response to the therapy was noted in all patients (100%), at any dosing regimen. Complete metabolic response, as detected by PET/CT, was observed in two patients (28.6%) treated at 0.5 and 1 mg/kg. Three patients of seven (42.9%) experienced grade 3-4 grade adverse events (AEs) from nivolumab, which included immune disorders. There was no correlation with nivolumab dosing regimen since severe AEs were documented in patients treated at 0.5, 1, or 3 mg/kg. All the patients are alive by the time of evaluation, 4/7 patients had the disease relapse at a median of 7 months (5 to 9) after initiation of the treatment. nivolumab may represent an efficient therapeutic tool in patients with HL relapse after allo-HSCT, however, followed by a considerable toxicity in some cases.

show abstract

Section: Discussionmentioning

confidence: 99%